Myotonic dystrophy

Jan 09, 2020

AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise

Sep 12, 2019

Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

Jun 13, 2019

Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting

Jun 12, 2019

MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophy

Apr 16, 2019

AMO Pharma Announces Launch of First Clinician-Completed Rating Scale for Congenital Myotonic Dystrophy Type 1

Oct 18, 2017

AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

Sep 25, 2017

AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

Jul 27, 2017

AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

May 30, 2017

AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy